Januvia Related Published Studies
Well-designed clinical trials related to Januvia (Sitagliptin)
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. [2011.09]
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. [2011.07]
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. [2011.06]
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. [2011.05]
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. [2011.03]
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. [2011.03]
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. [2011.03]
Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers. [2011.03]
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. [2011.02]
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. [2011.02]
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. [2011.01]
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes:
a pilot, double-blind, randomized, crossover trial. [2011]
A treatment strategy implementing combination therapy with sitagliptin and
metformin results in superior glycaemic control versus metformin monotherapy due
to a low rate of addition of antihyperglycaemic agents. [2011]
Substance P-induced skin inflammation is not modulated by a single dose of
sitagliptin in human volunteers. [2011]
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. [2010.10]
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. [2010.10]
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. [2010.08.07]
The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. [2010.08]
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. [2010.07]
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. [2010.06]
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. [2010.04.24]
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. [2010.04]
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. [2010.03]
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. [2010.02]
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. [2010.01]
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. [2010]
Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. [2010]
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. [2010]
Efficacy and safety of sitagliptin monotherapy compared with voglibose in
Japanese patients with type 2 diabetes: a randomized, double-blind trial. [2010]
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. [2009.08]
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus. [2009.08]
Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. [2009.03]
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. [2009.01]
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. [2008.02]
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. [2008.02]
Sitagliptin: a novel drug for the treatment of type 2 diabetes. [2007.09]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. [2007.09]
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. [2007.09]
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. [2007.08]
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. [2007.06]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. [2007.03]
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. [2007.03]
Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects. [2007.02]
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. [2007.02]
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. [2007.01]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. [2006.12]
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. [2006.12]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. [2006.11]
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. [2006.11]
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [2006.10]
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. [2006.10]
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. [2006.08]
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. [2006.01]
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. [2005.12]
Well-designed clinical trials possibly related to Januvia (Sitagliptin)
Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized,
double-blind, placebo-controlled studies in subjects with type 2 diabetes. [2012]
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. [2011.07]
Efficacy and safety of incretinbased therapies: clinical trial data. [2009.09]
Other research related to Januvia (Sitagliptin)
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in
patients of type 2 diabetes mellitus inadequately controlled with metformin
alone. [2012]
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4)
inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin,
and vildagliptin efficacy results. [2012]
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. [2011.11.07]
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. [2011.11]
Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. [2011.10]
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC Study. [2011.09.29]
Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. [2011.08.22]
[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]. [2011.07]
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists
compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus:
a systematic review and meta-analysis. [2011]
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the
clinical trials. [2011]
Sitagliptin more effectively achieves a composite endpoint for A1C reduction,
lack of hypoglycemia and no body weight gain compared with glipizide. [2011]
Liraglutide improves treatment satisfaction in people with Type 2 diabetes
compared with sitagliptin, each as an add on to metformin. [2011]
Weight-related quality of life, health utility, psychological well-being, and
satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone
after 26 weeks of treatment. [2011]
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. [2010.07]
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. [2010.07]
[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)] [2010.06.20]
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. [2010.06.08]
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. [2010.06]
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. [2010.05]
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. [2010.04.22]
Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. [2010.04]
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. [2010.04]
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes] [2010.03]
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. [2009.11]
Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. [2009.10]
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. [2009.10]
Effects of Colesevelam HCl, Rosiglitazone, or Sitagliptin on Glycemic Control and the Lipid Profile in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. [2009.09.28]
Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic. [2009.09]
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. [2009.07]
Impact of sitagliptin on markers of beta-cell function: a meta-analysis. [2009.05]
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. [2009.04]
Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. [2009.03]
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. [2009.03]
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. [2009.01]
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. [2008.10.27]
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. [2008.10]
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. [2008.09]
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. [2008.07]
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. [2008.07]
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. [2008.07]
New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. [2008.06]
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. [2008.06]
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. [2008.06]
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. [2008.05]
|
